Two Powerhouse Medications
Both semaglutide (brand names Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have transformed the weight loss landscape. But they aren't identical — understanding their differences can help you and your doctor choose the best option.
How They Work Differently
Semaglutide targets one receptor: GLP-1. It mimics the GLP-1 hormone to reduce appetite and slow digestion.
Tirzepatide targets two receptors: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). This dual-action approach may provide additional metabolic benefits.
Clinical Results Compared
- Semaglutide: Average weight loss of 15-17% of body weight in clinical trials
- Tirzepatide: Average weight loss of 20-22% of body weight in the SURMOUNT trials
Both medications showed significant improvements in blood sugar, blood pressure, and cholesterol levels.
Side Effects
Both medications share similar side effects, primarily gastrointestinal: nausea, constipation, and diarrhea — especially during the dose escalation phase. These typically improve over time.
Which Should You Choose?
The right medication depends on your individual health profile, weight loss goals, insurance coverage, and how your body responds to treatment. Our medical team at Monaco Health will help you navigate this decision based on your specific needs.
Schedule a free consultation to discuss which GLP-1 medication may be right for your weight loss journey.
